Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure
Xconomy
JULY 18, 2016
Evoke Pharma is taking a hit in the markets after announcing a Phase 3 trial on a gastroinetestinal drug for diabetes patients failed to meet its goals. Evoke’s late-stage study failed to show a significant benefit to the drug, EVK-001, versus placebo at all 41 of the sites that tested it nationally. per share as of 11:30 a.m.
Let's personalize your content